Bionomics Limited – NASDAQ:BNOX
Bionomics Limited stock price today
Bionomics Limited stock price monthly change
Bionomics Limited stock price quarterly change
Bionomics Limited stock price yearly change
Bionomics Limited key metrics
Market Cap | 800.30M |
Enterprise value | N/A |
P/E | -0.83 |
EV/Sales | -53.36 |
EV/EBITDA | 0.64 |
Price/Sales | 60.74 |
Price/Book | 0.33 |
PEG ratio | 0.01 |
EPS | -4.4 |
Revenue | 4.59M |
EBITDA | -21.65M |
Income | -28.08M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -8253.62% |
Oper. margin | -8095.14% |
Gross margin | 0% |
EBIT margin | -8095.14% |
EBITDA margin | -471.1% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBionomics Limited stock price history
Bionomics Limited stock forecast
Bionomics Limited financial statements
| Sep 2021 | 65.90K | -2.17M | -3298.93% |
|---|---|---|---|
| Dec 2021 | 123.05K | -9.48M | -7707.25% |
| Jun 2022 | 4.06M | -6.01M | -147.91% |
| Jun 2023 | 344.22K | -10.41M | -3026% |
| 2028 | 85.55M | -12.49M | -14.61% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2021 | 67842449 | 7.56M | 11.14% |
|---|---|---|---|
| Jun 2022 | 65310172 | 8.39M | 12.86% |
| Dec 2022 | 38333042 | 5.84M | 15.25% |
| Jun 2023 | 28642534 | 6.56M | 22.92% |
| Dec 2021 | -9.32M | 446.35K | 17.85M |
|---|---|---|---|
| Jun 2022 | -6.15M | 5.1K | 1.67M |
| Mar 2023 | 0 | 0 | -306K |
| Jun 2023 | -8.21M | 192.10K | -264.78K |
Bionomics Limited alternative data
| Mar 2024 | 8 |
|---|---|
| Apr 2024 | 8 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Bionomics Limited other data
-
What's the price of Bionomics Limited stock today?
One share of Bionomics Limited stock can currently be purchased for approximately $0.4.
-
When is Bionomics Limited's next earnings date?
Unfortunately, Bionomics Limited's (BNOX) next earnings date is currently unknown.
-
Does Bionomics Limited pay dividends?
No, Bionomics Limited does not pay dividends.
-
How much money does Bionomics Limited make?
Bionomics Limited has a market capitalization of 800.30M.
-
What is Bionomics Limited's stock symbol?
Bionomics Limited is traded on the NASDAQ under the ticker symbol "BNOX".
-
What is Bionomics Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Bionomics Limited?
Shares of Bionomics Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Bionomics Limited have?
As Jul 2024, Bionomics Limited employs 8 workers.
-
When Bionomics Limited went public?
Bionomics Limited is publicly traded company for more then 3 years since IPO on 16 Dec 2021.
-
What is Bionomics Limited's official website?
The official website for Bionomics Limited is bionomics.com.au.
-
Where are Bionomics Limited's headquarters?
Bionomics Limited is headquartered at 200 Greenhill Road, Eastwood, SA.
-
How can i contact Bionomics Limited?
Bionomics Limited's mailing address is 200 Greenhill Road, Eastwood, SA and company can be reached via phone at +61 8 8354 6100.
Bionomics Limited company profile:
Bionomics Limited
bionomics.com.auNASDAQ
8
Biotechnology
Healthcare
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Eastwood, SA 5063
CIK: 0001191070
ISIN: US09063M2052
CUSIP: 09063M205
